Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma Treated With Intensity-modulated Radiotherapy(IMRT): A Phase 3, Multicentre, Randomised Controlled Trial(CTVp1-NPC)

NCT05994170 is registered in ClinicalTrials.gov with Zhongshan People's Hospital, Guangdong, China as lead sponsor.

NCT NCT05994170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05994170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma Treated With Intensity-modulated Radiotherapy(IMRT): A Phase 3, Multicentre, Randomised Controlled Trial(CTVp1-NPC)
Lead sponsor
Zhongshan People's Hospital, Guangdong, China
Phase
Not applicable
Overall status
Recruiting
Start date
August 4, 2023
Completion date
September 1, 2029
Enrollment
454 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

intensity-modulated radiotherapy, nasopharyngeal carcinoma